Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2025-04-17 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于使用闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 贝达药业股份有限公司 regarding the use of idle raised funds for cash management. It details the board and supervisory committee meetings approving the use of up to 200 million RMB of idle raised funds for low-risk, short-term financial products. The document includes background on the raised funds, investment purpose, scope, risk control measures, and approvals. It is a regulatory announcement about the company's financing fund management and does not contain financial statements or detailed financial results. The document length is under 5,000 characters and it serves as a formal disclosure of a financing-related operational decision rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP).
2025-04-17 Chinese
2024年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2024 by 贝达药业股份有限公司. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2024, including financial and non-financial internal control defects, their definitions, and rectification status. The content is focused on internal control evaluation and audit opinions rather than full financial statements or annual performance. It does not contain quarterly or annual financial results, nor is it a brief announcement or presentation. This type of document aligns with an Audit Report / Information (AR) category, which includes standalone audit reports and internal control evaluations. The document length (5240 characters) supports it being a full report rather than a brief announcement. Therefore, the classification is AR with high confidence.
2025-04-17 Chinese
2024年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2024 年度监事会工作报告' which translates to '2024 Supervisory Board Work Report'. It details the supervisory board's activities, oversight of company operations, financial management, internal controls, related party transactions, and plans for 2025. The content is a comprehensive report on the supervisory board's work and oversight for the year 2024, including financial and governance aspects. It is not an announcement or a brief summary but a detailed report. This fits the category of a Management Report (MDA), which includes management's detailed explanation of financial results, business trends, and outlook. The document is 3575 characters long, which is relatively short but contains substantive content rather than just an announcement or certification. Therefore, the best classification is Management Reports (MDA).
2025-04-17 Chinese
2024年年度财务报告
Annual Report Classification · 100% confidence The document is titled '贝达药业股份有限公司 2024 年年度财务报告' which translates to 'Betta Pharmaceuticals Co., Ltd. 2024 Annual Financial Report'. It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes. It also includes an audit report with an unqualified opinion from a registered accounting firm dated April 16, 2025. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The presence of comprehensive financial data and audit opinion confirms this is the official annual report covering the company's full financial performance for the fiscal year 2024. Therefore, the document fits the definition of an Annual Report (10-K).
2025-04-17 Chinese
贝达药业股份有限公司章程（2025年4月）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Betta Pharmaceuticals Co. Ltd. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, and governance rules. It is a foundational governance document that sets out the internal rules and regulations of the company. There is no indication that this is an annual report, financial report, or announcement. The document is lengthy (15,000 characters) and is not a brief announcement or certification. The content aligns with the definition of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2025-04-17 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 19th meeting of the 4th Supervisory Board of Betta Pharmaceuticals Co., Ltd. It includes multiple agenda items such as approval of the 2024 Supervisory Board Work Report, 2024 Financial Final Report, 2024 Annual Report full text and summary, remuneration for supervisors, special report on the use of raised funds, cash management proposals, and the 2024 Internal Control Self-Evaluation Report. The document states that these reports and documents are disclosed elsewhere (on the CNINFO website) and will be submitted to the 2024 Annual General Meeting for approval. The document itself is a meeting resolution announcement rather than the full annual report or financial statements. It is relatively short (2620 characters) and primarily serves to announce the meeting decisions and the availability of the full reports elsewhere. According to the "Menu vs Meal" rule, this is an announcement of reports and resolutions, not the reports themselves. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories like Annual Report (10-K) or Management Reports (MDA).
2025-04-17 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.